RetinalGenix Technologies (RetinalGenix Technologies) Change In Working Capital : $0.33 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is RetinalGenix Technologies Change In Working Capital?

RetinalGenix Technologies's change in working capital for the quarter that ended in Mar. 2024 was $0.08 Mil.

RetinalGenix Technologies's change in working capital for the fiscal year that ended in Dec. 2023 was $0.41 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

RetinalGenix Technologies Change In Working Capital Historical Data

The historical data trend for RetinalGenix Technologies's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RetinalGenix Technologies Change In Working Capital Chart

RetinalGenix Technologies Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

0.09

0.16

0.23

0.41

RetinalGenix Technologies Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial										0.16	0.06	0.06	0.13	0.08

RetinalGenix Technologies Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.33 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

RetinalGenix Technologies Change In Working Capital Related Terms

Thank you for viewing the detailed overview of RetinalGenix Technologies's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

RetinalGenix Technologies (RetinalGenix Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RetinalGenix Technologies Inc (OTCPK:RTGN) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1450 North McDowell Boulevard, Suite 150, Petaluma, CA, USA, 94954

Website

https://www.retinalgenix.com

RetinalGenix Technologies Inc is an ophthalmic research and development company focused on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders, Its mission is to prevent vision loss and blindness due to diabetic retinopathy and maculopathy through early detection from the use of two devices: (1) Retinal Imaging Screening Device (RetinalGenixTM), being designed as a portable, high-resolution retinal imaging Diabetic screening system providing a 200-degree field of view without requiring pupil dilation; and (2) RetinalCamTM, being designed as a high-resolution home monitoring retinal imaging device and physician alert system offering real-time communication with physicians available 24/7.